UNFI-Manufactured EQUALINE Antacids Recalled Nationwide Over Metallic Contamination
UNITED NATURAL FOODS, INC. DBA UNFI faces a nationwide Class II recall for EQUALINE ultra strength calcium carbonate antacids due to metallic particle contamination. Initiated by Guardian Drug Co. Inc., this event impacts procurement and supply chain operations for distributors like SUPERVALU INC. Decision-makers must assess supplier quality controls and diversify sourcing for critical OTC ingredients, especially given Guardian Drug Co. Inc.'s recent history of similar contamination recalls, to mitigate significant business disruption and regulatory exposure.
FDA Initiates Nationwide Class II Recall for EQUALINE Calcium Carbonate Antacids
The U.S. Food and Drug Administration (FDA) has classified an ongoing Class II recall, D-0577-2026, for EQUALINE ultra strength antacid tablets, specifically the calcium carbonate 1000mg chewable tablets. This voluntary, firm-initiated recall commenced on May 28, 2026, by Guardian Drug Co. Inc. out of Dayton, NJ. The critical issue identified is the presence of small metallic particles within the chewable tablets, constituting a foreign substance that poses a potential health risk, although not typically life-threatening. For procurement directors and regulatory affairs heads, this event underscores the immediate need to verify product integrity across all incoming shipments of similar over-the-counter (OTC) antacids. The affected lot number is 1716089, with an expiration date of January 2029. This incident highlights a significant lapse in quality control within the manufacturing or packaging process, necessitating a thorough review of supplier qualification and material inspection protocols to prevent similar contaminations from entering the supply chain and impacting consumer safety.
Product Specifications and Extensive U.S. Distribution Network
The recalled product, marketed as EQUALINE ultra strength, antacid tablets, contains 1000mg of calcium carbonate per chewable tablet and is packaged as 72-count units. Specific product identifiers include NDC 41163-171-68, with associated UPCs 0041163466951 and 0041163254183. The product is also identified as EQU ULTRA STRENGTH ANTACID ASSORTED FRUIT 171AF (NDC 41163-171). While Guardian Drug Co. Inc. is the recalling firm, the product is distributed by SUPERVALU INC., based in Eden Prairie, MN, and manufactured by UNITED NATURAL FOODS, INC. DBA UNFI. The distribution pattern is extensive, covering the entire U.S.A. nationwide. For supply chain VPs and business development executives, this broad distribution means a significant logistical challenge in retrieving affected products from retail shelves and consumer hands. The involvement of multiple entities—manufacturer, distributor, and recalling firm—complicates the recall process, demanding clear communication and coordinated efforts to minimize market disruption and reputational damage across the supply chain.
Supply Chain Vulnerabilities for UNITED NATURAL FOODS, INC. DBA UNFI and Distributors
This recall directly impacts UNITED NATURAL FOODS, INC. DBA UNFI, identified as the manufacturer, and SUPERVALU INC., a key distributor. The presence of metallic particles points to potential vulnerabilities in UNFI's manufacturing processes, from raw material handling to final product packaging. For procurement directors, this necessitates an immediate audit of UNFI's quality management systems, particularly for calcium carbonate-based products and other chewable tablets. The nationwide distribution by SUPERVALU Inc. means a substantial operational burden, including reverse logistics, inventory write-offs, and potential financial penalties. Business development executives must consider the potential for brand erosion for both the EQUALINE brand and the associated distributors, as consumer trust in product safety is paramount. Proactive engagement with UNFI and its downstream partners is crucial to understand the root cause, implement robust corrective actions, and ensure future product integrity, thereby safeguarding market share and consumer confidence in the competitive OTC drug sector.
Pattern of Contamination: Guardian Drug Co. Inc.'s Recent Regulatory Challenges
This Class II recall for metallic contamination in calcium carbonate antacids is not an isolated incident for Guardian Drug Co. Inc., the recalling firm. ChemLifeIntel's intelligence indicates a concerning pattern, with Guardian Drug Co. Inc. facing at least two other nationwide Class II recalls for similar metallic contamination issues in antacid products, including HyVee Antacid, both published on June 10, 2026. This recurring problem suggests systemic deficiencies in their quality control and manufacturing processes, particularly concerning foreign substance detection. For regulatory affairs heads, this trend signals heightened scrutiny from the FDA on Guardian Drug Co. Inc.'s operations and potentially on the broader antacid manufacturing sector. Procurement teams sourcing from Guardian Drug Co. Inc. or its contract manufacturers must immediately reassess their supplier risk profiles and demand comprehensive corrective and preventive action plans (CAPAs) to avoid association with repeated quality failures and the significant operational and reputational costs that accompany them.
Strategic Sourcing for Calcium Carbonate: Mitigating Future Supply Disruptions
Given the ongoing recall of EQUALINE calcium carbonate antacids due to metallic particle contamination, procurement directors must re-evaluate their sourcing strategies for this critical active pharmaceutical ingredient (API) and finished dosage form. While specific alternative suppliers are not detailed in the available intelligence, the imperative is to diversify the supply base beyond single-source reliance, especially for high-volume OTC products like antacids. This involves identifying and rigorously qualifying new suppliers with demonstrable track records of cGMP compliance, robust quality control systems, and comprehensive foreign particulate detection capabilities. Qualification timelines can be extensive, often spanning 12-18 months, requiring proactive engagement. Supply chain VPs should initiate a multi-vendor strategy, exploring suppliers across diverse geographical regions to build resilience against localized quality issues or regulatory actions. This strategic shift is essential to ensure continuity of supply, minimize the impact of future recalls, and protect market access for essential medicines.
Post-Recall Actions and Enhanced Quality Control Imperatives
As this Class II recall remains ongoing, UNITED NATURAL FOODS, INC. DBA UNFI, Guardian Drug Co. Inc., and SUPERVALU INC. are expected to conduct a thorough root cause analysis to identify precisely how metallic particles entered the calcium carbonate antacid tablets. For regulatory affairs heads, this analysis must lead to robust corrective and preventive actions (CAPAs) that address the systemic issues, not just the symptoms. The FDA will closely monitor the effectiveness of these CAPAs, and failure to implement adequate controls could result in further regulatory actions, including potential Warning Letters or import alerts for facilities involved. Business development executives should anticipate increased scrutiny from retail partners and consumers regarding product safety. Investing in advanced inspection technologies, enhancing employee training on quality protocols, and implementing more stringent raw material testing are immediate imperatives to restore confidence and prevent future quality deviations. Proactive communication with stakeholders about remediation efforts will be critical for maintaining market trust.